Literature DB >> 30120199

Identification and characterization of ubiquitinylation sites in TAR DNA-binding protein of 43 kDa (TDP-43).

Friederike Hans1,2, Marita Eckert1,2, Felix von Zweydorf1, Christian Johannes Gloeckner1,3, Philipp J Kahle4,2.   

Abstract

TAR DNA-binding protein of 43 kDa (TDP-43) forms pathological aggregates in neurodegenerative diseases, particularly in certain forms of frontotemporal dementia and amyotrophic lateral sclerosis. Pathological modifications of TDP-43 include proteolytic fragmentation, phosphorylation, and ubiquitinylation. A pathognomonic TDP-43 C-terminal fragment (CTF) spanning amino acids 193-414 contains only four lysine residues that could be potentially ubiquitinylated. Here, serial mutagenesis of these four lysines to arginine revealed that not a single residue is responsible for the ubiquitinylation of mCherry-tagged CTF. Removal of all four lysines was necessary to suppress ubiquitinylation. Interestingly, Lys-408 substitution enhanced the pathological phosphorylation of the immediately adjacent serine residues 409/410 in the context of mCherry-CTF. Thus, Lys-408 ubiquitinylation appears to hinder Ser-409/410 phosphorylation in TDP-43 CTF. However, we did not observe the same effect for full-length TDP-43. We extended the mutagenesis study to full-length TDP-43 and performed MS. Ubiquitinylated lysine residues were identified in the nuclear localization sequence (NLS; Lys-84 and Lys-95) and RNA-binding region (mostly Lys-160, Lys-181, and Lys-263). Mutagenesis of Lys-84 confirmed its importance as the major determinant for nuclear import, whereas Lys-95 mutagenesis did not significantly affect TDP-43's nucleo-cytoplasmic distribution, solubility, aggregation, and RNA-processing activities. Nevertheless, the K95A mutant had significantly reduced Ser-409/410 phosphorylation, emphasizing the suspected interplay between TDP-43 ubiquitinylation and phosphorylation. Collectively, our analysis of TDP-43 ubiquitinylation sites indicates that the NLS residues Lys-84 and Lys-95 have more prominent roles in TDP-43 function than the more C-terminal lysines and suggests a link between specific ubiquitinylation events and pathological TDP-43 phosphorylation.
© 2018 Hans et al.

Entities:  

Keywords:  TDP-43; amyotrophic lateral sclerosis (ALS) (Lou Gehrig disease); frontotemporal dementia; mass spectrometry (MS); neurodegeneration; proteasome; protein aggregation; protein phosphorylation; site-directed mutagenesis; ubiquitylation (ubiquitination)

Mesh:

Substances:

Year:  2018        PMID: 30120199      PMCID: PMC6187624          DOI: 10.1074/jbc.RA118.003440

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  67 in total

Review 1.  Ubiquitin: same molecule, different degradation pathways.

Authors:  Michael J Clague; Sylvie Urbé
Journal:  Cell       Date:  2010-11-24       Impact factor: 41.582

Review 2.  Ubiquitin chain diversity at a glance.

Authors:  Masato Akutsu; Ivan Dikic; Anja Bremm
Journal:  J Cell Sci       Date:  2016-02-15       Impact factor: 5.285

3.  Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy.

Authors:  Nicole F Liachko; Chris R Guthrie; Brian C Kraemer
Journal:  J Neurosci       Date:  2010-12-01       Impact factor: 6.167

Review 4.  Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins.

Authors:  Antonia Ratti; Emanuele Buratti
Journal:  J Neurochem       Date:  2016-06-15       Impact factor: 5.372

5.  Parkin reverses TDP-43-induced cell death and failure of amino acid homeostasis.

Authors:  Michaeline Hebron; Wenqiang Chen; Matthew J Miessau; Irina Lonskaya; Charbel E-H Moussa
Journal:  J Neurochem       Date:  2013-12-19       Impact factor: 5.372

6.  Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system.

Authors:  Xiaoju Wang; Huadong Fan; Zheng Ying; Bin Li; Hongfeng Wang; Guanghui Wang
Journal:  Neurosci Lett       Date:  2009-11-26       Impact factor: 3.046

7.  Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Masato Hasegawa; Tetsuaki Arai; Takashi Nonaka; Fuyuki Kametani; Mari Yoshida; Yoshio Hashizume; Thomas G Beach; Emanuele Buratti; Francisco Baralle; Mitsuya Morita; Imaharu Nakano; Tatsuro Oda; Kuniaki Tsuchiya; Haruhiko Akiyama
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

Review 8.  Proteostasis impairment in ALS.

Authors:  Céline Ruegsegger; Smita Saxena
Journal:  Brain Res       Date:  2016-03-28       Impact factor: 3.252

9.  Evidence for ubiquitin-regulated nuclear and subnuclear trafficking among Paramyxovirinae matrix proteins.

Authors:  Mickey Pentecost; Ajay A Vashisht; Talia Lester; Tim Voros; Shannon M Beaty; Arnold Park; Yao E Wang; Tatyana E Yun; Alexander N Freiberg; James A Wohlschlegel; Benhur Lee
Journal:  PLoS Pathog       Date:  2015-03-17       Impact factor: 6.823

Review 10.  TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.

Authors:  Helen Ling; Eleanna Kara; Rina Bandopadhyay; John Hardy; Janice Holton; Georgia Xiromerisiou; Andrew Lees; Henry Houlden; Tamas Revesz
Journal:  Neurobiol Aging       Date:  2013-05-09       Impact factor: 4.673

View more
  14 in total

1.  Multiple distinct pathways lead to hyperubiquitylated insoluble TDP-43 protein independent of its translocation into stress granules.

Authors:  Friederike Hans; Hanna Glasebach; Philipp J Kahle
Journal:  J Biol Chem       Date:  2019-11-28       Impact factor: 5.157

2.  Frontotemporal Lobar Degeneration TDP-43-Immunoreactive Pathological Subtypes: Clinical and Mechanistic Significance.

Authors:  Manuela Neumann; Edward B Lee; Ian R Mackenzie
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD.

Authors:  Alistair Wood; Yuval Gurfinkel; Nicole Polain; Wesley Lamont; Sarah Lyn Rea
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

Review 4.  Multi-phaseted problems of TDP-43 in selective neuronal vulnerability in ALS.

Authors:  Kazuhide Asakawa; Hiroshi Handa; Koichi Kawakami
Journal:  Cell Mol Life Sci       Date:  2021-03-11       Impact factor: 9.261

Review 5.  Structural Insights Into TDP-43 and Effects of Post-translational Modifications.

Authors:  Liberty François-Moutal; Samantha Perez-Miller; David D Scott; Victor G Miranda; Niloufar Mollasalehi; May Khanna
Journal:  Front Mol Neurosci       Date:  2019-12-17       Impact factor: 5.639

Review 6.  Ubiquitin, Autophagy and Neurodegenerative Diseases.

Authors:  Yoshihisa Watanabe; Katsutoshi Taguchi; Masaki Tanaka
Journal:  Cells       Date:  2020-09-02       Impact factor: 6.600

Review 7.  TDP-43 Pathology in Alzheimer's Disease.

Authors:  Axel Meneses; Shunsuke Koga; Justin O'Leary; Dennis W Dickson; Guojun Bu; Na Zhao
Journal:  Mol Neurodegener       Date:  2021-12-20       Impact factor: 14.195

Review 8.  Liquid-Liquid Phase Separation of TDP-43 and FUS in Physiology and Pathology of Neurodegenerative Diseases.

Authors:  Jenny L Carey; Lin Guo
Journal:  Front Mol Biosci       Date:  2022-02-02

Review 9.  Ubiquitin signaling in neurodegenerative diseases: an autophagy and proteasome perspective.

Authors:  François Le Guerroué; Richard J Youle
Journal:  Cell Death Differ       Date:  2020-11-18       Impact factor: 12.067

10.  Cell-to-cell transmission of C9orf72 poly-(Gly-Ala) triggers key features of ALS/FTD.

Authors:  Kathrine D LaClair; Henrick Riemenschneider; Qihui Zhou; Bahram Khosravi; Frédéric Frottin; Nikola Mareljic; Mareike Czuppa; Daniel Farny; Hannelore Hartmann; Meike Michaelsen; Thomas Arzberger; F Ulrich Hartl; Mark S Hipp; Dieter Edbauer
Journal:  EMBO J       Date:  2020-03-16       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.